ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Indian firm buys Teva U.K. business

by Jean-François Tremblay
October 17, 2016 | APPEARED IN VOLUME 94, ISSUE 41

India’s Intas Pharmaceuticals will pay $740 million to buy the U.K. and Ireland business of Actavis Generics from Teva Pharmaceutical Industries. The European Union said Teva had to divest the business to win approval for its 2015 acquisition of Actavis Generics from Allergan. Intas says the new business will double its sales in Europe to $500 million annually and make it a top-20 player in generics.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment